# EDGAR Filing Document

**Accession Number:** 0001630212
**File Stem:** 0001213900-26-046208
**Filing Date:** 2026-4
**Character Count:** 22993
**Document Hash:** 604d4d3d76774ede59973052b71aea3a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-046208.hdr.sgml**: 20260421

**ACCESSION NUMBER**: 0001213900-26-046208

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260218

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260421

**DATE AS OF CHANGE**: 20260421

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Avalon GloboCare Corp.
- **CENTRAL INDEX KEY:** 0001630212
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-COMPUTER PROGRAMMING SERVICES [7371]
- **ORGANIZATION NAME:** 06 Technology
- **EIN:** 471685128
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38728
- **FILM NUMBER:** 26879909

**BUSINESS ADDRESS:**
- **STREET 1:** 4400 ROUTE 9
- **STREET 2:** SUITE 3100
- **CITY:** FREEHOLD
- **STATE:** NJ
- **ZIP:** 07728
- **BUSINESS PHONE:** 732-780-4400

**MAIL ADDRESS:**
- **STREET 1:** 4400 ROUTE 9
- **STREET 2:** SUITE 3100
- **CITY:** FREEHOLD
- **STATE:** NJ
- **ZIP:** 07728

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avalon Globocare Corp.
- **DATE OF NAME CHANGE:** 20161018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GLOBAL TECHNOLOGIES CORP
- **DATE OF NAME CHANGE:** 20150108

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K/A**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of**

**the Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **February 18, 2026**

**<u>AVALON GLOBOCARE CORP.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38728** | **47-1685128** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |  | Identification Number) |

---

**4400 Route 9 South, Suite 3100, Freehold, NJ 07728**

(Address of principal executive offices, including zip code)

**(732) 780-4400**

(Registrant's telephone number, including area code)

**N/A**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | ALBT | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 **Explanatory Note:**

On February 18, 2026, Avalon Globocare Corp. (the "Company") filed a Current Report on Form 8-K (the "Original Report") reporting the Company and Wenzhao Lu (the "Purchaser") entered into an Amended and Restated Membership Interest Purchase Agreement (the "Amended MIPA"), pursuant to which the Company sold to the Purchaser 100% of the membership interests of Avalon RT 9 Properties, LLC, a wholly owned subsidiary of the Company ("Avalon RT9"). Avalon RT9 was the owner of real property located at 4400 Route 9 South, Freehold, New Jersey 07728 , where the Company maintains its principal office space. The Original Report indicated that pro forma financial information required by Item 9.01(b) of Form 8-K would be filed by amendment.

This Current Report on Form 8-K/A amends the Original Report to provide the unaudited pro forma consolidated financial information required by Item 9.01(b) of Form 8-K. Except as described herein, this Form 8-K/A does not amend, modify, or update any other information contained in the Original Report.

**Item 9.01. Financial Statements and Exhibits.**

*(b)* *Pro forma financial information\*.* 

The unaudited pro forma consolidated financial information of the Company giving effect to the Amended MIPA consisting of

(i) the unaudited pro forma consolidated balance sheet as of December 31, 2025, and

(ii) the unaudited pro forma consolidated statements of operations and comprehensive loss of the Company for the years ended December 31, 2025 and 2024.

\*Filed as Exhibit 99.1

(d) *Exhibits.*

---

| | |
|:---|:---|
| **Exhibit No.** | **Exhibit** |
| 99.1 | [Unaudited pro forma consolidated financial information](ea028709201ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **AVALON GLOBOCARE CORP.** | **AVALON GLOBOCARE CORP.** |
| Dated: April 21, 2026 | By: | */s/ Luisa Ingargiola* |
|  | Name: | Luisa Ingargiola |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL INFORMATION**

The following unaudited pro forma consolidated balance sheet and statements of operations and comprehensive loss are based upon the historical consolidated financial statements of Avalon GloboCare Corp. (the "Company"). The unaudited pro forma consolidated financial information has been prepared to illustrate the effect of the sale (the "Sale") of Avalon RT 9 Properties, LLC, a wholly owned subsidiary of the Company ("Avalon RT 9"). For a detailed description of the Sale, please see Note [1] of the accompanying unaudited pro forma consolidated financial information.

The unaudited pro forma consolidated balance sheet as of December 31, 2025 has been prepared by including the audited historical consolidated balance sheet of the Company as of December 31, 2025, adjusted to reflect the pro forma effect as if the Sale had been consummated on that date. The unaudited pro forma consolidated statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024 have been prepared by including the Company's historical consolidated statements of operations and comprehensive loss, adjusted to reflect the pro forma effect as if the Sale had been consummated on January 1, 2024.

The historical consolidated financial statements referred to above for the Company were included in its Annual Reports on Form 10-K for the years ended December 31, 2025 and 2024, previously filed with the Securities and Exchange Commission (the "SEC"). The accompanying unaudited pro forma consolidated financial information and the historical consolidated financial information presented herein should be read in conjunction with the historical consolidated financial statements and notes thereto of the Company.

The unaudited pro forma consolidated balance sheet and statements of operations and comprehensive loss include pro forma adjustments which reflect transactions and events that (a) are directly attributable to the Sale, (b) are factually supportable, and (c) with respect to the statements of operations, have a continuing impact on consolidated results of operations. The pro forma adjustments are described in the accompanying notes to the unaudited pro forma consolidated financial information.

The unaudited pro forma consolidated financial information was prepared for informational purposes only and is not necessarily indicative of the financial position or results of operations that would have occurred if the Sale had been completed on the dates indicated, nor is it indicative of the future financial position or results of operations of the Company. Assumptions and estimates underlying the pro forma adjustments are described in the accompanying notes, which should be read in conjunction with the unaudited pro forma consolidated financial information. The accounting for the Sale is dependent upon final balances related to the assets and liabilities at the closing date that have yet to progress to a stage where there is sufficient information for a definitive measurement. Due to the fact that the unaudited pro forma consolidated financial information has been prepared based upon preliminary estimates and account balances other than those on the actual Sale closing date, the final amounts recorded for the Sale may differ materially from the pro forma consolidated financial information presented.

The unaudited pro forma consolidated financial information does not reflect future events that may occur after the Sale, including potential restructuring and related general and administrative cost savings. The pro forma adjustments are subject to change and are based upon currently available information.

**AVALON GLOBOCARE CORP. AND SUBSIDIARIES**

**UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET**

**As of December 31, 2025**

---

| | | | |
|:---|:---|:---|:---|
|  |<br>Historical | Pro Forma<br>Adjustments |<br>Pro Forma |
| ASSETS |  |  |  |
| CURRENT ASSETS: |  |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $109091 | $- | $109091 |
| &nbsp;&nbsp;&nbsp;Receivable from sale of equity method investment | 748000 |  | 748000 |
| &nbsp;&nbsp;&nbsp;Prepaid expense and other current assets | 282170 |  | 282170 |
| &nbsp;&nbsp;&nbsp;Current assets of discontinued operations | 356616 | (356616) b | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | 1495877 | (356616) | 1139261 |
| NON-CURRENT ASSETS: |  |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 727 |  | 727 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 2158167 |  | 2158167 |
| &nbsp;&nbsp;&nbsp;Goodwill | 12808197 |  | 12808197 |
| &nbsp;&nbsp;&nbsp;Non-current assets of discontinued operations | 6937769 | (6937769) b | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Non-current Assets | 21904860 | (6937769) | 14967091 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Assets | $23400737 | $(7294385) | $16106352 |
| &nbsp;&nbsp;&nbsp;LIABILITIES AND EQUITY |  |  |  |
| CURRENT LIABILITIES: |  |  |  |
| &nbsp;&nbsp;&nbsp;Accrued professional fees | $1832606 | $- | $1832606 |
| &nbsp;&nbsp;&nbsp;Accrued research and development fees | 153772 |  | 153772 |
| &nbsp;&nbsp;&nbsp;Accrued payroll liability and compensation | 1072553 |  | 1072553 |
| &nbsp;&nbsp;&nbsp;Accrued litigation settlement | 363450 |  | 363450 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities and other payables | 281063 |  | 281063 |
| &nbsp;&nbsp;&nbsp;Accrued liabilities and other payables - related parties | 100000 |  | 100000 |
| &nbsp;&nbsp;&nbsp;Operating lease obligation | 6000 |  | 6000 |
| &nbsp;&nbsp;&nbsp;Advance from pending sale of noncontrolling interest - related party | 3158078 | (3158078) a |  |
| &nbsp;&nbsp;&nbsp;Derivative liability | 34156 |  | 34156 |
| &nbsp;&nbsp;&nbsp;Stock subscription liability | 150000 |  | 150000 |
| &nbsp;&nbsp;&nbsp;Bridge loan payable, net | 197341 |  | 197341 |
| &nbsp;&nbsp;&nbsp;Convertible note payable, net | 737018 |  | 737018 |
| &nbsp;&nbsp;&nbsp;Current liabilities of discontinued operations | 6061077 | (6061077) b | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | 14147114 | (9219155) | 4927959 |
| NON-CURRENT LIABILITIES: |  |  |  |
| &nbsp;&nbsp;&nbsp;Non-current liabilities of discontinued operations | 23515 | (23515) b | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Non-current Liabilities | 23515 | (23515) b | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | 14170629 | (9242670) | 4927959 |
| EQUITY: |  |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.0001 par value; 10,000,000 shares authorized; |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series C Convertible Preferred Stock, 3,800 shares issued and outstanding at December 31, 2025; Liquidation preference $3.8 million at December 31, 2025 | 3790000 |  | 3790000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series D Convertible Preferred Stock, 5,000 shares issued and outstanding at December 31, 2025; Liquidation preference $5 million at December 31, 2025 | 8837527 |  | 8837527 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series E Convertible Preferred Stock, 19,500 shares issued and outstanding at December 31, 2025; Liquidation preference $19.5 million at December 31, 2025 | 14916753 |  | 14916753 |
| &nbsp;&nbsp;&nbsp;Common stock, $0.0001 par value; 100,000,000 shares authorized;4,857,476 shares issued and 4,854,009 shares outstanding at December 31, 2025 | 486 |  | 486 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 88376767 | 1948285 c | 90325052 |
| &nbsp;&nbsp;&nbsp;Less: common stock held in treasury, at cost; 3,467 shares at December 31, 2025 | (522500) |  | (522500) |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (105934101) |  | (105934101) |
| &nbsp;&nbsp;&nbsp;Statutory reserve | 6578 |  | 6578 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (241402) | - | (241402) |
| &nbsp;&nbsp;&nbsp;Total Avalon GloboCare Corp. stockholders' equity | 9230108 | 1948285 | 11178393 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | - | - | - |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Equity | 9230108 | 1948285 | 11178393 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities and Equity | $23400737 | $(7294385) | $16106352 |

---

See notes to unaudited pro forma consolidated financial information.

**AVALON GLOBOCARE CORP. AND SUBSIDIARIES**

**UNAUDITED PRO FROMA CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS**

**For the Year Ended December 31, 2025**

---

| | | | |
|:---|:---|:---|:---|
|  |<br>Historical | Pro Forma<br>Adjustments |<br>Pro Forma |
| INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO | $392677 | $- | $392677 |
| OTHER OPERATING EXPENSES: |  |  |  |
| &nbsp;&nbsp;&nbsp;Advertising and marketing expenses | 843497 |  | 843497 |
| &nbsp;&nbsp;&nbsp;Professional fees | 5254207 |  | 5254207 |
| &nbsp;&nbsp;&nbsp;Compensation and related benefits | 1101574 |  | 1101574 |
| &nbsp;&nbsp;&nbsp;Other general and administrative expenses | 784758 | - | 784758 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Operating Expenses | 7984036 | - | 7984036 |
| LOSS FROM OPERATIONS | (7591359) | - | (7591359) |
| OTHER (EXPENSE) INCOME |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense - amortization of debt discount and debt issuance costs | (1136412) |  | (1136412) |
| &nbsp;&nbsp;&nbsp;Interest expense - other | (320282) |  | (320282) |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | 538213 |  | 538213 |
| &nbsp;&nbsp;&nbsp;Loss on extinguishment of debt | (9076587) |  | (9076587) |
| &nbsp;&nbsp;&nbsp;Other income | 67554 | - | 67554 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Expense, net | (9927514) | - | (9927514) |
| LOSS BEFORE INCOME TAXES | (17518873) |  | (17518873) |
| INCOME TAXES | - | - | - |
| NET LOSS FROM CONTINUING OPERATIONS | (17518873) |  | (17518873) |
| NET LOSS FROM DISCONTINUED OPERATIONS | (742103) | 742103 d | - |
| NET LOSS | $(18260976) | $742103 | $(17518873) |
| LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | - | - | - |
| NET LOSS AFTER NONCONTROLLING INTEREST | (18260976) | 742103 | (17518873) |
| DEEMED CONTRIBUTION ON EXCHANGE OF EQUITY INSTRUMENTS | 162473 | - | 162473 |
| NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | $(18098503) | $742103 | $(17356400) |
| NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS: |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted, continuing operations | $(5.41) | $- | $(5.41) |
| &nbsp;&nbsp;&nbsp;Basic and diluted, discontinued operations | (0.23) | 0.23 | - |
| &nbsp;&nbsp;&nbsp;Basic and diluted | $(5.64) | $0.23 | $(5.41) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | 3210779 | 3210779 | 3210779 |
| COMPREHENSIVE LOSS: |  |  |  |
| &nbsp;&nbsp;&nbsp;NET LOSS | $(18260976) | $742103 | $(17518873) |
| &nbsp;&nbsp;&nbsp;OTHER COMPREHENSIVE LOSS FROM CONTINUED OPERATIONS |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized foreign currency translation loss | (9402) | (9402) | (9402) |
| &nbsp;&nbsp;&nbsp;COMPREHENSIVE LOSS | (18270378) | 732701 | (17528275) |
| &nbsp;&nbsp;&nbsp;LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | - | - | - |
| &nbsp;&nbsp;&nbsp;COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | $(18270378) | $732701 | $(17528275) |

---

See notes to unaudited pro forma consolidated financial information.

**AVALON GLOBOCARE CORP. AND SUBSIDIARIES**

**UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS**

**For the Year Ended December 31, 2024**

---

| | | | |
|:---|:---|:---|:---|
|  |<br>Historical | Pro Forma<br>Adjustments |<br>Pro Forma |
| REAL PROPERTY RENTAL REVENUE | $1333403 | $(1333403) e | $- |
| REAL PROPERTY OPERATING EXPENSES | 1065574 | (1065574) e | - |
| REAL PROPERTY OPERATING INCOME | 267829 | (267829) | - |
| LOSS FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO | (846588) | - | (846588) |
| OTHER OPERATING EXPENSES: |  |  |  |
| &nbsp;&nbsp;&nbsp;Advertising and marketing expenses | 237671 |  | 237671 |
| &nbsp;&nbsp;&nbsp;Professional fees | 1822105 | (231837) e | 1590268 |
| &nbsp;&nbsp;&nbsp;Compensation and related benefits | 1431328 | (122474) e | 1308854 |
| &nbsp;&nbsp;&nbsp;Other general and administrative expenses | 857869 | - | 857869 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Operating Expenses | 4348973 | (354311) | 3994662 |
| LOSS FROM OPERATIONS | (4927732) | 86482 | (4841250) |
| OTHER (EXPENSE) INCOME |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest expense - amortization of debt discount and debt issuance costs | (1411042) | 119228 e | (1291814) |
| &nbsp;&nbsp;&nbsp;Interest expense - other | (983486) | 658000 e | (325486) |
| &nbsp;&nbsp;&nbsp;Interest expense - related party | (42445) |  | (42445) |
| &nbsp;&nbsp;&nbsp;Debt modification charge | (838794) |  | (838794) |
| &nbsp;&nbsp;&nbsp;Change in fair value of derivative liability | 374365 |  | 374365 |
| &nbsp;&nbsp;&nbsp;Other expense | (74260) | 80 e | (74180) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Other Expense, net | (2975662) | 777308 | (2198354) |
| LOSS BEFORE INCOME TAXES | (7903394) | 863790 | (7039604) |
| INCOME TAXES | - | - | - |
| NET LOSS | $(7903394) | $863790 | $(7039604) |
| LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | - | - | - |
| NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | $(7903394) | $863790 | $(7039604) |
| NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS: |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | $(8.44) | $0.92 | $(7.52) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: |  |  |  |
| &nbsp;&nbsp;&nbsp;Basic and diluted | 936614 | 936614 | 936614 |
| COMPREHENSIVE LOSS: |  |  |  |
| &nbsp;&nbsp;&nbsp;NET LOSS | $(7903394) | $863790 | $(7039604) |
| &nbsp;&nbsp;&nbsp;OTHER COMPREHENSIVE LOSS |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unrealized foreign currency translation loss | (273) | - | (273) |
| &nbsp;&nbsp;&nbsp;COMPREHENSIVE LOSS | (7903667) | 863790 | (7039877) |
| &nbsp;&nbsp;&nbsp;LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | - | - | - |
| &nbsp;&nbsp;&nbsp;COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | $(7903667) | $863790 | $(7039877) |

---

See notes to unaudited pro forma consolidated financial information.

**[1] Description of Sale**

On February 18, 2026, the Company and Wenzhao Lu (the "Purchaser"), the Chairman of the Company's Board of Directors, entered into an Amended and Restated Membership Interest Purchase Agreement (the "Amended MIPA"), pursuant to which the Company sold to the Purchaser 100% of the membership interests of Avalon RT 9 Properties, LLC, a wholly owned subsidiary of the Company ("Avalon RT 9"), for $9,000,000.

**[2] Basis of Presentation**

The unaudited pro forma consolidated financial information is prepared pursuant to Article 11 of Regulation S-X. The unaudited pro forma consolidated balance sheet and statements of operations and comprehensive loss are based upon the historical consolidated financial statements of the Company, which were included in its Annual Reports on Form 10-K for the fiscal years ended December 31, 2025 and 2024, previously filed with the SEC. The unaudited pro forma consolidated balance sheet as of December 31, 2025 has been prepared by including the audited historical consolidated balance sheet of the Company as of December 31, 2025, adjusted to reflect the pro forma effect as if the Sale had been consummated on that date. The unaudited pro forma consolidated statements of operations and comprehensive loss for the years ended December 31, 2025 and 2024 have been prepared by including the Company's historical consolidated statements of operations and comprehensive loss, adjusted to reflect the pro forma effect as if the Sale had been consummated on January 1, 2024.

**[3] Pro Forma Adjustments**

The following pro forma adjustments are included in the unaudited pro forma consolidated balance sheet and/or the unaudited pro forma consolidated statements of operations and comprehensive loss:

&nbsp;&nbsp;&nbsp;&nbsp;a. Reflects the elimination of advance received from the Purchaser of approximately $3 million.

&nbsp;&nbsp;&nbsp;&nbsp;b. Reflects the elimination of Avalon RT 9's assets and liabilities.

&nbsp;&nbsp;&nbsp;&nbsp;c. Reflects the effect on additional paid-in capital related to the estimated gain on sale of Avalon RT 9
to Mr. Lu, the Company's chairman of the Board of Directors. The Company recorded proceeds in excess of its carrying value (approximately
$2 million) to additional paid-in capital as a result of the capital transaction with related party under applicable SEC regulations.

&nbsp;&nbsp;&nbsp;&nbsp;d. Reflects the elimination of the historical net loss from discontinued operations attributable to the sale
of Avalon RT 9.

&nbsp;&nbsp;&nbsp;&nbsp;e. Reflects the elimination of the historical real property rental revenue, real property operating expenses,
other operating expenses, and other expense attributable to the sale of Avalon RT 9.